{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:45:05Z","timestamp":1791945905576,"version":"4.3.4"},"reference-count":44,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["movementdisorders.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The classical complement pathway is implicated in the progression of neurodegenerative disease through its ability to drive aberrant removal of synapses, neuroinflammation, and neuronal damage. ANX005 is a humanized monoclonal antibody targeting C1q that blocks classical complement pathway activation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim was to assess the safety, pharmacokinetics (PK), pharmacodynamics, and clinical activity of ANX005 in patients with Huntington's disease (HD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>ANX005\u2010HD\u201001 (NCT04514367) was a multicenter, open\u2010label, phase 1b study in patients with early\u2010manifest HD. Primary endpoints included safety, tolerability, PK, and complement C1q and C4a\/C4 levels in the serum and cerebrospinal fluid (CSF). Exploratory clinical activity endpoints included changes from baseline in composite Unified Huntington's Disease Rating Scale (cUHDRS) and component scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All patients who received study drug (n\u2009=\u200928) experienced \u22651 treatment\u2010emergent adverse event, mostly transient infusion\u2010related reactions on the first dose. Three patients with elevated baseline antinuclear antibodies withdrew from the study due to treatment\u2010related AEs (pneumonitis) or serious AEs (systemic lupus erythematous, hemolysis). Twenty\u2010three patients (82.1%) received all planned ANX005 infusions. Steady\u2010state PK was achieved by week 6, with full saturation of ANX005 observed in serum and the CSF. Stabilization or possible improvement in cUHDRS and total functional capacity through 36\u2009weeks was observed in a patient subgroup with higher baseline complement activity, based on baseline C4a\/C4 ratio in CSF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Overall, AEs with ANX005 administration were manageable, and most patients received all planned doses. Evidence of clinical improvement with ANX005 was observed in patients with higher baseline complement activity, supporting future study in patients with HD. \u00a9 2026 The Author(s).\n                      <jats:italic>Movement Disorders<\/jats:italic>\n                      published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/mds.70229","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T11:05:37Z","timestamp":1772967937000},"page":"1492-1501","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["An Open\u2010Label Phase 1b Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of\n                    <scp>ANX005<\/scp>\n                    in Patients with Huntington's Disease"],"prefix":"10.1002","volume":"41","author":[{"given":"Rajeev","family":"Kumar","sequence":"first","affiliation":[{"name":"Rocky Mountain Movement Disorders Center  Englewood Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinky","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Evergreen Healthcare  Kirkland Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Anderson","sequence":"additional","affiliation":[{"name":"Georgetown University  Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Claassen","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Dean","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Duker","sequence":"additional","affiliation":[{"name":"UC Gardner Neuroscience Institute  Cincinnati Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burton","family":"Scott","sequence":"additional","affiliation":[{"name":"Duke University  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Hoehn","sequence":"additional","affiliation":[{"name":"Annexon Biosciences  Brisbane California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Mongan","sequence":"additional","affiliation":[{"name":"Annexon Biosciences  Brisbane California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Lin","sequence":"additional","affiliation":[{"name":"Annexon Biosciences  Brisbane California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Cahir\u2010McFarland","sequence":"additional","affiliation":[{"name":"Annexon Biosciences  Brisbane California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Taylor","sequence":"additional","affiliation":[{"name":"Annexon Biosciences  Brisbane California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Morrison","sequence":"additional","affiliation":[{"name":"Annexon Biosciences  Brisbane California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted","family":"Yednock","sequence":"additional","affiliation":[{"name":"Annexon Biosciences  Brisbane California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Keswani","sequence":"additional","affiliation":[{"name":"Annexon Biosciences  Brisbane California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk\u2010Andre","family":"Kroon","sequence":"additional","affiliation":[{"name":"Annexon Biosciences  Brisbane California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60111-1"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005072-199805000-00001"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2011.08.052"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02566-3"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1999.7170"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.M800231-MCP200"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012969"},{"key":"e_1_2_10_9_1","unstructured":"SuriP MonganA Andrews\u2010ZwillingY et al.A model incorporating levels of complement activation more accurately predicts Huntington's disease progression than neurofilament light [poster]; Huntington Study Group Annual Meeting November 4\u20136 2021 Virtual 2021."},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00454-4"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23236"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01919-8"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8145-9"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-0400-0"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/1091581817740873"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad8373"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-016-0291-x"},{"key":"e_1_2_10_18_1","unstructured":"HuynhC TassoniA MathurV et al.C1q inhibition reduces neurodegenerative damage and improves survival in the HD R6\/2 mouse model [poster]; Society for Neuroscience (SfN) November 12\u201316 2022 San Diego CA2022."},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004743"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2019-000326"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126442"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-320106"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature21029"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0058-z"},{"issue":"2","key":"e_1_2_10_25_1","first-page":"226","article-title":"Efficacy and safety of targeted immunotherapy with ANX005 in treating Guillain\u2010Barr\u00e9 syndrome: a phase 3 multicenter study (abstract #1058)","volume":"5","author":"Kroon HA","year":"2024","journal-title":"RRNMF Neuromuscul J"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2013.10.010"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2011.39"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2015.03.007"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2015.06.002"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2020.07.018"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc2888"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.779"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2003715"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.104970"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28489"},{"key":"e_1_2_10_36_1","unstructured":"TrundellD PalermoG SchobelS LongJD LeavittBR TabriziSJ.Validity reliability ability to detect change and meaningful within\u2010patient change of the cUHDRS; European Huntington's Disease Network Plenary Meeting September 14\u201316 2018 Vienna Austria [poster]."},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.98.18_supplement.3867"},{"issue":"1","key":"e_1_2_10_38_1","article-title":"E01\u2009widespread loss of presynaptic terminal marker SV2A in early Huntington disease [abstract]","volume":"92","author":"Delva A","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1145649"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031688"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-094136"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577767"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26626"},{"key":"e_1_2_10_44_1","unstructured":"MonganA GuoC VolmanV et al.Positive changes to neuroinflammatory biomarkers consistent with improvement in cUHDRS in patients treated with ANX005 an inhibitor of C1q and the classical complement pathway [poster]; 18th Annual Huntington's Disease Therapeutics Conference April 24\u201027 2023 Dubrovnik Croatia."},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00121-1"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.70229","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mds.70229","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.70229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:02:47Z","timestamp":1791943367000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.70229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/mds.70229"],"URL":"https:\/\/doi.org\/10.1002\/mds.70229","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"assertion":[{"value":"2024-12-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}